Piramal Pharma Limited — Results, 08-01-2025: Reply to Clarification- Financial results

Piramal Pharma Limited reported its financial performance for the quarter and half-year ended September 30, 2024.

Consolidated revenue experienced a robust year-over-year growth of 28.5%, reaching ₹1,037.09 crore, driven by increased demand and strategic market expansion efforts. The profit before tax was ₹35.38 crore, compared to a loss of ₹101.05 crore in the previous period. This turnaround highlights the company's focus on operational improvements and cost management. Earnings Per Share (EPS) for the period stands at ₹0.45, up significantly from a loss of ₹1.29 per share previously.

Operational costs saw a reduction of 5% quarter-over-quarter, reflecting effective cost management initiatives. However, there were notable increases in areas such as finance costs, which remained elevated at ₹214.60 crore, primarily due to higher debt levels.

The cash flow statement indicates a net decrease in cash and cash equivalents of ₹152.22 crore, with net cash generated from operating activities totaling ₹184.71 crore. The company has a strong balance sheet, although current obligations remain high, warranting careful monitoring of liquidity.

Strategic focus appears centered on innovation and market penetration, aligning with ongoing investments in capacity and R&D. Investor sentiment may lean toward a 'hold' status as the company continues to push through recovery while managing debt levels effectively. Future profitability hinges on sustaining revenue growth and controlling operational expenses.